Jeremy D. Richmon

Jeremy D. Richmon

Auto-generated profile, based on publicly available information

Jeremy D. Richmon

Department of Otolaryngology—Head and Neck Surgery Massachusetts Eye and Ear and Harvard Medical School Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Gland Surgery
Verified
Journal Article
Closed access
PDF file
JRJeremy D. Richmon
Jeremy D. Richmon
HKHoon Yub Kim
Hoon Yub Kim
Remote-access approaches to the thyroid gland have seen a rapid evolution recently with the development of various techniques to minimize the cosmetic and quality-of-life impact of a visible scar. Most approaches have required significantly more tissue dissection and have been limited in their extent to treat contralateral disease. The transoral approach is the most recent iteration of “scarless” thyroidectomy and offers various advantages over other techniques including less tissue dissection, equal access to both sides of the neck, and a superb midline view of the anatomy. Transoral thyroidectomy may be performed with either laparoscopic or robotic technology, each with various advantages and disadvantages. Herein, we discuss our experience with transoral robotic thyroidectomy (TORT).

15 April 2021 in Head & Neck
Verified
Journal Article
Closed access
PDF file
AHAndrew J. Holcomb
Andrew J. Holcomb
MHMatthew Herberg
Matthew Herberg
MSMadeleine Strohl
Madeleine Strohl
EOEdgar Ochoa
Edgar Ochoa
AFAllen L. Feng
Allen L. Feng
JRJeremy D. Richmon
Jeremy D. Richmon

14 July 2020 in Oral Oncology
Verified
Journal Article
Closed access
RFRobert L. Ferris
Robert L. Ferris
YFYael Flamand
Yael Flamand
FHF. Christopher Holsinger
F. Christopher Holsinger
GWGregory S. Weinstein
Gregory S. Weinstein
HQHarry Quon
Harry Quon
BBBarbara Burtness
Barbara Burtness

5 June 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
AFAllen Lee Feng
Allen Lee Feng
CRChristopher R. Razavi
Christopher R. Razavi
PLPranav Lakshminarayanan
Pranav Lakshminarayanan
ZAZaid Ashai
Zaid Ashai
KOKevin Olds
Kevin Olds
JRJeremy D. Richmon
Jeremy D. Richmon

20 May 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
MBMichael Bryan
Michael Bryan
LALing Aye
Ling Aye
DDDipon Das
Dipon Das
SHShun Hirayama
Shun Hirayama
YAYana Al-inaya
Yana Al-inaya
DFDaniel Faden
Daniel Faden
Purpose: The incidence of human papillomavirus (HPV)–associated head and neck squamous cell carcinoma (HPV + HNSCC) is increasing in the United States. Currently, there are no early detection approaches for HPV + HNSCC. Two blood-based analytes for early detection and diagnosis of HPV + HNSCC, circulating tumor HPV DNA (ctHPVDNA) and HPV early protein antibodies (HPV Ab), show promise, yet current approaches lack adequate diagnostic accuracy for broad clinical utility. Further, performance metrics across various assays for detecting these analytes alone or in combination have not been compared head-to-head. To address these limitations and knowledge gaps, we developed a multifeature HPV whole-genome sequencing (WGS) liquid biopsy for improved low-level ctHPVDNA detection. We defined the performance characteristics of this WGS-based approach and compared it head-to-head with existing blood-based HPV detection approaches to determine the optimal single or combinatorial biomarker strategy for a future prospective study of HPV + HNSCC early detection. Experimental Design: We tested blood samples from 304 participants: 152 patients with untreated incident HPV + HNSCC (77% stage I) and 152 general population control patients. We compared WGS-based ctHPVDNA detection, single-plex Droplet Digital PCR (ddPCR)–based ctHPVDNA detection, multiplex ddPCR-based ctHPVDNA detection, multiplex HPV Ab detection, and clinical standard-of-care tissue biopsy, benchmarked to gold-standard HPV + HNSCC tissue diagnosis. We then modeled the operational feasibility of these approaches as screening biomarkers for HPV + HNSCC. Results: HPV WGS sensitivity and specificity were 98.7% and 98.7%, respectively. Single-plex ddPCR sensitivity and specificity were 94.2% and 98.6%, respectively. Multiplex ddPCR sensitivity and specificity were 90.6% and 96.3%, respectively. HPV Ab sensitivity and specificity were 86.4% and 96.3%, respectively. A combinatorial approach using both HPV WGS and HPV Ab yielded a sensitivity and specificity of 87.4% and 98.8%, respectively. In a head-to-head comparison, HPV WGS demonstrated significantly improved diagnostic accuracy compared with ddPCR (Youden index for HPV WGS, 0.99 vs. ddPCR, 0.90; P < 0.001), HPV Ab (HPV WGS, 0.99 vs. HPV Ab, 0.83; P < 0.001), and clinical workup (HPV WGS, 0.99 vs. clinical workup, 0.82; P < 0.001), which was maintained when evaluating only early-stage disease cases. For men ages 55 to 74, HPV WGS yielded the lowest number needed to screen (2,903 men) and the highest positive predictive value (2.6). Conclusions: HPV WGS–based ctHPVDNA detection demonstrated the highest sensitivity, specificity, and diagnostic accuracy and thus the lowest number needed to screen and highest positive predictive value compared with ddPCR-based ctHPVDNA detection, HPV Ab–based detection, and combinatorial approaches. These results highlight the promise of HPV WGS liquid biopsy for screening and early detection of HPV + HNSCC and the need for modeling and cost-effectiveness studies to evaluate and guide screening implementation.

21 April 2021 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
MBMustafa G. Bulbul
Mustafa G. Bulbul
MWMichael Wu
Michael Wu
DLDerrick Lin
Derrick Lin
KEKevin Emerick
Kevin Emerick
DDDaniel Deschler
Daniel Deschler
MVMark A. Varvares
Mark A. Varvares